SOUTH SAN FRANCISCO, Calif., April 28 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that it has named Bruce F. Scharschmidt, MD as Chief Medical Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)
Dr. Scharschmidt joins Hyperion from NOVARTIS where he most recently served as Vice President of Scientific Affairs for NOVARTIS Vaccines. He previously held senior positions in Chiron's Corporate Group as well as in Chiron's Vaccines and Biopharmaceuticals Development organizations where he was intimately involved in the strategic direction and management of key research and development programs. Before joining Chiron, Dr. Scharschmidt was Chief of Gastroenterology and Professor of Medicine at the University of California San Francisco. He is Board Certified in Internal Medicine and Gastroenterology and has served as Associate Editor of Gastroenterology, Editor-in-Chief of The Journal of Clinical Investigation, and President of the American Society for Clinical Investigation.
"Hyperion has made exceptional progress in a short time," commented Dr. Scharschmidt in discussing his new role. "I am enthusiastic about becoming part of the organization and working with my colleagues both at Hyperion and in the GI and liver communities to bring products to patients in need."
"Bruce's technical expertise in gastroenterology and liver disease as well as the drug development experience he gained at Chiron make him a significant asset in our company's effort to become a global leader in the development and commercialization of hepatology and gastrointestinal therapies that address orphan or underserved patient populations with unmet medical needs," said Chris Rivera, President and Chief Executive Officer of Hyperion Therapeutics, Inc. "We look forward to Bruce's many contributions."
About Hyperion Therapeutics
Hyperion Therapeutics is a fully-integrated specialty therapeutics company committed to becoming a global leader in the development and commercialization of hepatology and gastrointestinal therapies that address orphan or underserved patient populations with unmet medical needs. Hyperion's commercial operations division currently markets two products in the United States for urea cycle disorder. The Company is also conducting two phase II trials, one in the chronic treatment of urea cycle disorder and the other in the treatment of acute hepatic encephalopathy. Hyperion is headquartered in South San Francisco, CA. For additional information, visit: http://www.hyperiontx.com.
SOURCE Hyperion Therapeutics, Inc.
